Skip to main content
[Preprint]. 2021 Mar 12:2021.02.14.21251704. Originally published 2021 Feb 18. [Version 2] doi: 10.1101/2021.02.14.21251704

Figure 3. COVID-19 vaccines elicit potent but dose-dependent neutralizing responses against SARS-CoV-2 regardless of age or sex.

Figure 3.

(A) Titers that achieve 50% pseudovirus neutralization (pNT50) of wild-type SARS-CoV-2 are plotted for the following cohorts: (i) pre-pandemic individuals who were never vaccinated or infected with SARS-CoV-2 (pre-pandemic, white circles, n = 1,220); (ii) vaccine recipients that received only one dose of the BNT162b2 vaccine or were <7 days from their second dose (BNT162b2 – 1 dose, light blue triangles, n = 14); (iii) vaccine recipients ≥7 days following their second dose of BNT162b2 vaccine (BNT162b2 – 2 dose, blue circles, n = 30); (iv) vaccine recipients that received only one dose of the mRNA-1273 vaccine or were <7 days from their second dose (mRNA-1273 - 1 dose, pink diamonds, n = 27), and (v) vaccine recipients ≥7 days following their second dose of the mRNA-1273 vaccine (mRNA-1273 - 2 dose, red squares, n = 35).

(B) Pseudovirus neutralization (pNT50) of wild-type SARS-CoV-2 is plotted versus time postvaccination. The first dose (“dose #1”) of both BNT162b2 (blue) and mRNA-1273 (red) vaccines occurred on day 0. The second dose of the BNT162b2 vaccine occurred approximately 21 days after the first dose (“dose #2” in blue text) and for the mRNA-1273 vaccine occurred approximately 29 days after the first dose (“dose #2” in red text). Groups of vaccinees are the same as in (A). (C) Total anti-RBD (wild type) antibody levels measured by a quantitative ELISA against the wildtype RBD antigen versus neutralization of wild-type SARS-CoV-2 pseudovirus are presented. ELISAs were performed in duplicate and average values were used. Groups of vaccinees are the same as in (A).

(D) Neutralization of wild-type SARS-CoV-2 pseudovirus is compared between female and male vaccinees. Bars and error bars indicate mean and standard deviation. Groups of vaccinees are the same as in (A).

(E) Neutralization of wild-type SARS-CoV-2 pseudovirus is plotted against age of vaccine recipient. Groups of vaccinees are the same as in (A).